Bayer

Bayer’s investigational therapy, ²²⁵Ac-PSMA-Trillium, shows promise for advanced prostate cancer. This targeted radionuclide therapy uses alpha-emitting ²²⁵Ac and a PSMA-targeting ligand to attack cancer cells. Clinical trial results are being reviewed for efficacy, safety, and commercial viability. The therapy could position Bayer as a leader in radiopharmaceuticals, though manufacturing and cost challenges remain. It represents a significant advancement beyond standard treatments, offering hope for overcoming resistance and improving patient outcomes.